24/7MN (NASDAQ: CYAD) Celyad Oncology shares are moving up in pre-market as news of the FDA lifting its clinical hold on upcoming phase 1b trial.

August 1, 2022

Shares are up 44% on 2.4 million in volume on more than 15,900 trades as of this post. The stock is $2.48 a share.

[mstock id=”73007″ asset=”cyad”]

https://www.businesswire.com/news/home/20220731005044/en/Celyad-Oncology-Announces-FDA-Lifts-Clinical-Hold-of-CYAD-101-002-Phase-1b-Trial

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.